CGIM
CRVS icon

Cannon Global Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Cannon Global Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,000
Closed -$111K – 86
2025
Q1 		$111K Buy
+35,000
New +$165K 0.2% 69

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannon Global Investment Management's CRVS Position: Q2 2025 in Review

Cannon Global Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 35,000 shares — an estimated $111K sold.

Cannon Global Investment Management first reported a position in CRVS in Q1 2025 and held it in 1 quarter. The position peaked at $111K in Q1 2025. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Cannon Global Investment Management reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 35,000 Corvus Pharmaceuticals shares in Q2 2025, an estimated $111K.
  • Cannon Global Investment Management first reported a position in Corvus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Corvus Pharmaceuticals position peaked at $111K in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Cannon Global Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.